Methods for phenotyping of leukemias
View Patent ↗Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the β-catenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets.
1. A method of phenotyping chronic myelogenous leukemia (CML), the method comprising:
combining a hematologic sample from a patient suspected of CML with specific binding members that are sufficient to distinguish the distribution of cells with hematopoietic stem and progenitor subsets;
determining the distribution of progenitor cells between said subsets compared to a normal hematologic sample,
wherein CML chronic phase is typified by an expansion of megakaryocyte erythroid progenitors (MEP); CML accelerated phase is characterized by increased common myeloid progenitors (CMP); CML myeloid blast crisis is characterized by an increased granulocyte macrophage progenitors (GMP); and CML drug resistant phase is characterized by increased hematopoietic stem cells, compared with said normal hematologic sample.
2. The method according to claim 1 , wherein said specific binding members are antibodies.
3. The method according to claim 2 , wherein said antibodies include specificities for CD34 and CD38.
4. The method of claim 1 , wherein said hematologic sample is blood.
5. The method of claim 1 , wherein said hematologic sample is bone marrow.
6. The method of claim 1 , wherein the specific binding members comprise antibodies specific for CD34, CD38, IL-3α, and CD45RA, where the distribution of hematopoietic stem cells (CD34 + CD38 − ); common myeloid progenitor cells (CD34 + CD38 + CD45RA − IL-3Rα lo ); common myeloid progenitors (CD34 + CD38 + CD45RA + IL-3Rα lo ), megakaryocyte erythroid progenitors (CD34 + CD38 + CD45RA IL-3Rα 31 ), or granulocyte macrophage progenitors (CD34 + CD38 + IL-3Rα + CD45RA + ) distinguishes the progression of CML in the patient.
7. The method of claim 6 , further comprising the step of determining the presence of activated β-catenin levels in the hematologic sample.